@article{PrommersbergerHudecekNerreter2020,
  author    = {Prommersberger, Sabrina and Hudecek, Michael and Nerreter, Thomas},
  title     = {Antibody-Based CAR T Cells Produced by Lentiviral Transduction},
  series = {Current Protocols in Immunology},
  volume    = {128},
  journal   = {Current Protocols in Immunology},
  number    = {1},
  doi       = {10.1002/cpim.93},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-215497},
  year      = {2020},
  abstract  = {One promising approach to treat hematologic malignancies is the usage of patient-derived CAR T cells. There are continuous efforts to improve the function of these cells, to optimize their receptor, and to use them for the treatment of additional types of cancer and especially solid tumors. In this protocol, an easy and reliable approach for CAR T cell generation is described. T cells are first isolated from peripheral blood (here: leukoreduction system chambers) and afterwards activated for one day with anti-CD3/CD28 Dynabeads. The gene transfer is performed by lentiviral transduction and gene transfer rate can be verified by flowcytometric analysis. Six days after transduction, the stimulatory Dynabeads are removed. T cells are cultured in interleukin-2 conditioned medium for several days for expansion. There is an option to expand CAR T cells further by co-incubation with irradiated, antigen-expressing feeder cell lines. The CAR T cells are ready to use after 10 (without feeder cell expansion) to 24 days (with feeder cell expansion).},
  language  = {en}
}
@article{SeifEinseleLoeffler2019,
  author    = {Seif, Michelle and Einsele, Hermann and L{\"o}ffler, J{\"u}rgen},
  title     = {CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases},
  series = {Frontiers in Immunology},
  volume    = {10},
  journal   = {Frontiers in Immunology},
  number    = {2711},
  issn      = {1664-3224},
  doi       = {10.3389/fimmu.2019.02711},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-195596},
  year      = {2019},
  abstract  = {Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types of non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia, respectively. The success of adoptive CAR T cell therapy for cancer has inspired researchers to develop CARs for the treatment of infectious diseases. Here, we review the main achievements in CAR T cell therapy targeting viral infections, including Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus, Human Cytomegalovirus, and opportunistic fungal infections such as invasive aspergillosis.},
  language  = {en}
}